Home Tags DREAMM-1 study

Tag: DREAMM-1 study

EHA 2019: Belantamab Mafodotin in Patients with R/R Multple Myeloma

New, updated, data on belantamab mafodotin, also known as GSK2857916, an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC), were presented at the 24th...

GSK2857916 Demonstrates 60% Response Rate in Heavily Pre-treated Relapsed/Refractory Multiple Myeloma...

The investigational BCMA antibody-drug conjugate GSK2857916, also known as J6M0-mcMMAF, recently awarded Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and...